Brodalumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Interleukin 17 receptor A |
| Clinical data | |
| Trade names | Siliq, Kyntheum, Lumicef |
| Other names | KHK4827, AMG 827 |
| License data |
|
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6372H9840N1712O1988S52 |
| Molar mass | 143905.93 g·mol−1 |
| (what is this?) (verify) | |
Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases.[2][3][4]
In February 2017, it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.[5]
- ^ "Regulatory Decision Summary for Siliq". 23 October 2014. Archived from the original on 7 June 2022. Retrieved 10 June 2022.
- ^ a b "Siliq- brodalumab injection". DailyMed. 12 June 2020. Archived from the original on 18 March 2021. Retrieved 8 June 2022.
- ^ a b "Kyntheum EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 13 September 2021. Retrieved 8 June 2022.
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab" (PDF). American Medical Association. Archived (PDF) from the original on 1 February 2016. Retrieved 8 September 2011.
- ^ "FDA approves new psoriasis drug" (Press release). U.S. Food and Drug Administration. 15 February 2017. Archived from the original on 11 December 2019. Retrieved 18 February 2017.